Gamma knife surgery for facial nerve schwannomas. by Litré, Claude Fabien et al.
GAMMA KNIFE SURGERY FOR FACIAL
NERVE SCHWANNOMAS
OBJECTIVE: Radical resection of facial nerve schwannomas classically implies a high
risk of severe facial palsy. Owing to the rarity of facial palsy after gamma knife surgery
(GKS) of vestibular schwannomas, functional evaluation after GKS seems rational in
this specific group of patients. To our knowledge, no previous similar evaluation exists
in the literature.
METHODS: Of 1783 schwannomas of the cerebellopontine angles treated by GKS at
Timone University Hospital between July 1992 and May 2003, 11 were diagnosed as
originating from the facial nerve. Criteria for this diagnosis were the involvement of the
tympanic or mastoid segment of the facial nerve (n ! 9) and/or preoperative observa-
tion of a facial nerve deficit that had occurred during previous microsurgery (two
patients). The rare occurrence of facial palsy after vestibular schwannoma radiosurgery,
usually within 18 months of treatment, has been considered only in the patients with
more than 2 years of follow-up (n ! 9).
RESULTS: Six of these patients experienced a previous spontaneous facial palsy on one
(n ! 4) or several occasions (n ! 2). A normal motor facial function was observed in
only three patients before GKS (House-Brackmann Grade II in six patients, Grade III in
one patient, Grade IV in one patient). The median follow-up period was 39 months
(range, 18–84 mo). At the time of the last follow-up examination, no patients had devel-
oped a new facial palsy or experienced deterioration of a preexisting facial palsy and
three patients had improvement of a preoperative facial palsy. Ten out of the 11 tumors
are stable or decreased in size; in the other, a microsurgical resection of the tumor had
been recommended owing to the development of a cyst. Clinical management owing
to the specificity and heterogeneity of this group of patients has required the develop-
ment of an original classification of four anatomic subtypes presenting different clini-
cal and surgical difficulties.
CONCLUSION: This first study demonstrates that radiosurgery allows treatment of these
patients while preserving normal motor facial function. Such an advantage should lead
to the consideration of GKS as a first treatment option for small- to medium-size facial
nerve schwannomas.
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Facial nerve schwannomas (FNS) representless than 1% of intrapetrous tumors (9),whereas vestibular schwannomas repre-
sent 8% (1, 7) of intracranial tumors (10 per
million population). Complete tumor resection
generally requires the sacrifice of the facial
nerve. With successful interposition of a nerve
graft or hypoglossofacial anastomosis, a facial
nerve recovery is never better than a House-
Brackmann Grade III with obvious psychoso-
cial consequences. In this context, any possible
therapeutic alternative that could allow better
preservation of facial function must be studied.
The efficacy of stereotactic radiosurgery has
already been demonstrated in the treatment of
intracranial benign tumors, especially for
vestibular schwannomas. Because facial nerve
palsy (10, 15) is an exceptional event after
gamma knife surgery (GKS) treatment ("1%),
use of GKS seems to be an interesting ap-
proach when aiming for functional preserva-
tion of the facial nerve.
PATIENTS AND METHODS
A total of 1783 cerebellopontine angle (CPA) schwannomas
were operated using GKS and evaluated prospectively between
June 1992 and April 2006 at Timone University Hospital. Of
these, 11 proved to be FNS. The diagnosis of FNS was based on
the following criteria in nine patients: geniculate ganglion inva-
sion and/or invasion of one or more than one segment of the
facial nerve in its intrapetrous course and/or temporary spon-
taneous facial palsy. In the other two patients, the diagnosis
was based on previous microsurgical observation. None of
these lesions were found in the context of neurofibromatosis.
There were seven women and four men with a mean age of
46 years (range, 22–87 yr) at the time of GKS.
Tumor Classification
The lesions have been classified according to an original
anatomic classification defined by the topography of the origin
of the intrapetrous schwannoma (Fig. 1). Functional signs
(Table 1) were mainly constituted by facial nerve dysfunction in
55% of the patients (facial palsy with one temporary, hemifacial
spasm case) followed by cochleovestibular signs in 46%
(hypoacousis, tinnitus, vertigo, imbalance) (Table 2).
Clinical evaluation of our patients was based on the House-
Brackmann facial grading system (5) and the Gardner and
Robertson classification (3) for hearing. Facial function was
graded before GKS (Grade I, three patients; Grade II, six
patients; Grade III, one patient; Grade IV, one patient). The
hearing level was graded as Class 1 in three patients, Class 2 in
three patients, Class 3 in three patients, and Class 5 in two
patients. Another team had previously operated on two
patients, but the surgical procedure was interrupted at an
early stage to preserve facial function because the tumor was
obviously invading the facial nerve. In Patients 3 and 9, the
facial nerve was Grade II; the hearing level was Gardner 5
and 3, respectively.
All patients were admitted to the hospital the day before the
operation for clinical preparation and completion of all of the
required information. Tonal and vocal audiometry, auditory
evoked responses, and vestibular tests were systematically per-
formed the day before GKS. The radiosurgical procedure was
performed after light sedation. A Type G stereotactic frame was
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TABLE 1. Clinical presentation of the patients in this series
Patient Age House- Hearing Radiological
no. (yr)/sex Symptoms Brackmann grade grade type
1 42/F Hypoacousis, tinnitus, imbalance, vertigo Grade I Class III Type I
2 66/M Hypoacousis, tinnitus, imbalance Grade I Class III Type I
3 52/F Hypoacousis, tinnitus, imbalance Grade IIa Class III Type IV
4 22/M Hypoacousis, imbalance, vertigo Grade II Class I Type I
5 46/F Facial palsy, tinnitus, hemifacial spasm Grade III Class I Type II
6 26/F Hemifacial spasm, palsy (transient) Grade II Class I Type I
7 87/F Facial palsy, imbalance, hemifacial Grade II Class V Type I
spasm, hypoacousis
8 55/M Hemifacial spasm Grade II Class I Type I
9 36/F Hemifacial spasm, tinnitus, hypoacousis, vertigo Grade II Class Va Type II
10 48/F Facial palsy Grade IV Class II Type I
11 25/M No symptoms Grade I Class II Type I
FIGURE 1. Topographic classification of facial nerve schwannomas.
Images are obtained from a fused bone window computed tomographic
scan with magnetic resonance imaging (MRI) sequences. The tumor mar-
gin is delimited by the outline, which represents the 50% isodose.
a Postoperative effects.
positioned under local anesthesia. High resolution magnetic
resonance imaging (MRI) scans (Siemens 1.5-Tesla; Siemens
Medical Solutions, Erlangen, Germany) were performed in
stereotactic conditions. Axial T2 sequence constructive interfer-
ence in steady state and T1-weighted volumetric MRI pulse
sequence scans were performed. Computed tomographic scans
in bone windows were systematically performed to identify
the petrous bone anatomy and to check the lack of distortion
from the MRI scan. The first tumor volume assessment was in
volumetric condition, determined by the gamma plan station.
The mean tumor volume was 888 mm3 (range, 48–2253 mm3).
The mean peripheral isodose
was the 50% isodose with an
average isodose of 13 Gy
(range, 10–16 Gy) (Fig. 2). The
average number of isocenters
was 13 (range, 1–33).
The final decision in terms
of the marginal dose to be
used takes into account vari-
ous different data, including
the results of functional test-
ing (hearing and facial levels)
and the topography of the
FNS. After removal of the
frame, patients spent one
night in the neurosurgical
department. After clinical
evaluation the following day,
all were able to return to their
normal daily and professional
activities.
RESULTS
The patients were sequen-
tially followed at 6 months
and 1, 2, 3, 5, and 7 years.
Each control included clinical
examination and MRI scans.
The mean clinical and radiological follow-up period was
39 months (range, 18–84 mo). Nine patients have been followed
for more than 2 years (Table 3).
Tumor Control
At the 6-month follow-up examination, tumor size was
considered unchanged in six patients and increased in five;
at the 1-year follow-up examination, tumor size decreased in
three of these. For the nine patients who were followed for
more than 2 years after treatment, criteria of decreased size
was obtained in three patients, stabilized in five patients,
and increased in one patient. In this latter case, we observed
a global increase of tumor volume owing to cyst develop-
ment (Fig. 3). Microsurgical resection of this tumor was
recommended.
Functional Clinical Result
We observed an improvement of the functional signs in 11
patients. Resolution of hemifacial spasm was observed in two
patients. In one patient, a total facial palsy recovered. An im-
provement of facial nerve function from Grade II to Grade I
was observed in two patients, and improvement of facial nerve
function from Grade 4 to Grade 2 was observed in one patient.
Facial grade remained unchanged in the other patients (Table 4).
One patient experienced recovery of balance problems and
a clear decrease in tinnitus, which led to hearing improve-
ment. Patients with a useful hearing level at the preliminary
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TABLE 2. Classification of facial nerve schwannomas
Type I The tumor is localized on the geniculate ganglion.
Type II The tumor is a dumbbell-shape on the geniculate gang-
lion, labyrinthine segment, internal auditory canal, and
cerebellopontine angle cistern.
Type III The tumor develops in the tympanic and/or vertical
segments of the facial nerve.
Type IV The tumor develops in the internal auditory canal or
the cerebellopontine angle without invasion of the
fallopian canal or the geniculate ganglion. This category
is difficult to distinguish from the vestibular schwannoma
using radiological criteria. In this group, diagnosis was
usually based on a previous microsurgical attempt.
FIGURE 2. Dose planning for a Type 2 FNS.
examination maintained this at time of their last follow-up




The facial nerve emerges from the pontomedullary sulcus
near the cochleovestibular nerve, courses in the CPA transver-
sally, and enters the internal auditory canal with an anterosupe-
rior position. At the fundus of the internal auditory canal, the
facial nerve penetrates the facial canal just in front of a small
osseous vertical crest known as the “Bill bar.” The first horizon-
tal portion of the facial canal contains the facial nerve
(labyrinthine segment) and the intermediate nerve of Wrisberg.
The facial canal quickly leaves the region of the vestibule and
approaches the geniculate fossa, which contains the geniculate
ganglion. It then courses posteriorly and slightly laterally, thus
forming an acute 75-degree angle with variations that have been
extensively described in textbooks (13). It extends from the
geniculate fossa to the posterior wall of the tympanum and dis-
plays a close relationship with the loop of the lateral semicircu-
lar canal. The vertical portion of the facial canal extends from
the second turn to the stylomastoid foramen. It is nearly recti-
linear and forms an angle ranging from 95 to 125 degrees with
the tympanic portion of the facial canal. It runs through the
mastoid process, and thus merits the name of mastoid portion.
Diagnosis of FNS
FNS are rare tumors affecting both men and women equally.
Such tumors may be diagnosed regardless of the age of the
patient, but middle-aged people are predominantly affected.
Clinical manifestations are heterogeneous, depending on tumor
origin and extension. The primary symptoms are linked to
facial nerve dysfunction, regardless of the location of the tumor
on the facial nerve. Hemifacial weakness or hemifacial spasm
of sudden or progressive onset is the major symptom. Transient
and recurrent deficit is typical of the disease. Isolated dry eye
or dysgeusia may occur in cases of isolated involvement of the
geniculate ganglion or geniculate suprapetrous nerve.
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TABLE 3. Treatment and follow-up of our patients










1 10/18 1672 Stable N 54/decreased
2 12/14 963 Stable Y 24/stable
3a 12/33 2253 Stable N 28/stable
4 12/19 644 Increased Y 48/decreased
5 12/7 385 Stable N 18/stable
6 16/1 48 Increased N 84/decreased
7 11/17 207 Stable Y 36/stable
8 12/1 87 Stable N 30/decreased
9a 10/12 1669 Increased Y 60/increased
(cyst )
10 Increased N 20/stable
11 Stable N 32/stable
FIGURE 3. MRI scans showing the evolution of an
FNS after radiosurgery, with development of a cyst.
TABLE 4. Hearing status of patients with initial useful hearinga
Patient Volume Dose PTA GR Follow- PTA GR Delta Functional
no. Type (mm3) Gy before (dB) before up (yr) after (dB) after (dB) deficit (GR)
6 I 48 16 5.00 1 5 13.75 1 8.75 No
4 I 644 12 16.25 1 3 43.75 2 27.50 No
8 I 87 12 25.00 1 3 27.50 1 2.50 No
a Subtotal surgical removal.
a PTA, pure tone average; GR, Gardner Robertson score.
Otological and vestibular manifestations are also frequently
encountered. Imbalance and vertigo indicate that the tumor
affects the vestibular system in the case of CPA or internal audi-
tory canal involvement. Sensorial hearing deficit or tinnitus
indicates a cochlear nerve dysfunction in the CPA or internal
auditory canal, although the cochlea is generally not directly
involved by the tumor. Conductive hearing loss or the sensa-
tion of a blocked ear is typical of middle ear invasion. Diag-
nosis is based on high-resolution neuroimaging. Computed
tomographic scans show an enlargement of a segment of the
fallopian canal with homogeneous bone erosion, whereas MRI
scans show the enhanced tumor mass on a segment of the
nerve. In cases of geniculate fossa invasion, the tumor may
extend upward in the middle fossa, and may sometimes dis-
play cystic transformation. In an extensive review of the liter-
ature conducted over more than three decades (17), the tumor
location was described as follows: labyrinthine, 43%; tympanic,
42%; vertical segment, 36%; and CPA, 17%. Owing to refine-
ment in imaging techniques, the diagnosis is now made earlier
and the origin of the tumor can be more accurately defined. It
has recently been postulated that FNS predominantly develop
from the geniculate ganglion and petrosal nerves (19). Taken
collectively, the data obtained from the range of clinical presen-
tation and neuroimaging findings led us to establish an origi-
nal classification of FNS.
Timing and Modalities of Treatment
FNS are benign tumors that are supposed to display slow
growth, but little is known about their natural history. In a
recent study, a cohort of 13 patients was followed conserva-
tively (12). It has been shown that facial nerve deterioration
was observed in 38% of patients during a median follow-up
period of 6 years (range, 1–19 yr). This information is important
to take into account during the treatment decision process.
When treatment is recommended, microsurgical radical
removal was traditionally considered the treatment of choice.
Technical aspects of tumor removal depend on tumor origin,
extension, hearing level, and preexisting deficits. The main con-
sequence of tumor extirpation is facial nerve palsy. The realiza-
tion of facial nerve anastomosis using an interposed cable graft
or hypoglossofacial anastomosis partially reduces the deficit.
However, even in the best case scenario, the level of recovery
that can be reached is never better than Grade III. In rare cases
of extrafascicular growth of the nerve or in the case of genicu-
late suprapetrous nerve involvement, the nerve may be pre-
served (17), but this situation cannot be planned before the oper-
ative period. Consequently, several authors propose a “wait and
see” strategy and recommend radical resection after deteriora-
tion of facial motor nerve function. In parallel, it has been
shown that the occurrence of facial nerve palsy never exceeds
0.5% after GKS treatment (14) with a 97% rate of long-term
tumor control, whereas the facial nerve is always in close rela-
tionship with the tumor that is exposed to radiation. Taken col-
lectively, these observations led us to consider that radiosurgery
could represent a safe and efficient alternative to conventional
microsurgical removal of FNS. The present study is the first
report that focuses on a series of patients who have been treated
homogeneously with a state of the art technique. In 1999,
Mabanta et al. (11) reported the absence of short-term worsen-
ing of facial motor function in two patients treated with linear
accelerator-based radiosurgery, but no definitive conclusion
could be drawn from these reports (Table 5). In terms of tumor
control, the length of the follow-up period is still too short to
provide definitive data concerning tumor control. However,
50% of the patients have been followed for more than 3 years
without tumor growth. Notwithstanding, this period is long
enough to provide reliable functional results. Facial nerve func-
tion did not worsen for any patient, which compares favorably
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TABLE 5. Comparison of series from the literaturea
EvolutionNo. of Follow-up, recurrence/
Series (ref. no.) patients Therapy Hearing Facial function tumor progression
Sherman et al., 10 Microsurgery 2 worsened, 7 stable, 2 worsened, 5 stable, 39.8 mo, 1 patient
2002 (17) 1 enhanced 3 enhanced
Fichten et al., 7 Microsurgery 6 worsened, 7 worsened
2006 (2) 1 enhanced
Hasegawa et al., 2 Radiosurgery 1 enhanced, 2 stable 42 mo, 0
1999 (4) Gamma knife radiosurgery 1 stable
Mabanta et al., 2 with 6 Radiosurgery LINAC 2 stable 2 stable 32 mo, 0
1999 (11) schwannomas
Ulku et al., 4 Surgery Not available 1 stable, 1 worsened, 38 mo, 0
2004 (18) 2 enhanced
Current series 11 (2 with Gamma knife 11 stable 3 enhanced, 39 mo,
surgery) radiosurgery 8 stable 1 patientb
a LINAC, linear accelerator.
b Patient already operated (evolution with a cyst).
to microsurgery. This result is also interesting because most
patients presented with facial nerve deficit before radiosurgery;
thus, it would have been expected that radio-induced neuropa-
thy might occur more often when the nerves have already been
damaged. This situation is comparable to what has already been
observed for meningiomas affecting oculomotor nerves. In these
cases, it is usual to observe a recovery of the oculomotor palsy
after GKS (16). Of particular interest is the question of whether
or not complete palsy may recover after GKS, because restora-
tive microsurgery of the nerve is able to improve the motion to
Grade III. Hearing level was also preserved in all patients in the
present series, whereas the intrapetrous neuro-otological struc-
tures are jeopardized by open microsurgery.
CONCLUSION
Surgical management of FNS yields the risk of severe and
permanent deficit of cochleovestibular and facial nerve deficit.
In the present study, we have shown that GKS treatment was
an interesting option, permitting tumor control and functional
preservation in small to mid-sized tumors. Treatment of addi-
tional patients with longer follow-up periods after GKS should
confirm these preliminary data. The decision regarding early
proactive treatment remains debatable. If tumor volume
exceeds a 3-cm diameter or if the facial nerve deficit is severe
and permanent, it may be more valuable to recommend micro-
surgical removal and nerve reconstruction.
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COMMENTS
Virtually no center outside of Marseille has achieved such remark-able results in managing acoustic neuromas or the much-rarer
facial schwannomas. This report describes the outcomes, which are
generally quite favorable, of patients who received radiosurgery as a
primary management strategy. Most patients were diagnosed by char-
acteristic imaging, although two had prior surgery. The major outcome
factor after microsurgery was a virtually certain facial palsy. After
gamma knife surgery, functional facial nerve preservation as well as
hearing preservation were possible. In general, schwannomas seemed
to respond well, although each had its own idiosyncrasies. In our expe-
rience, trigeminal nerve sheath tumors are much more likely to have
transient tumoral enlargement at 4–12 months, and this is sometimes
associated with temporary sensory dysfunction. In contrast, transient
enlargement of acoustic neuromas occurs in fewer than 5% of patients.
Facial schwannomas and jugular bulb schwannomas also respond well
to radiosurgery, and in most cases this includes excellent motor preser-
vation. This report argues favorably for the role of gamma knife sur-
gery as a primary management strategy: patients can expect tumor
control, hearing preservation (in those who had hearing at presenta-
tion), and facial nerve function maintenance.
L. Dade Lunsford
Pittsburgh, Pennsylvania
Litre et al. from the Timone University Hospital in Marseille havedocumented, for the first time, outcomes after radiosurgery of facial
nerve schwannomas. The logic of this approach is clear: facial nerve
outcomes after resection are typically poor, whereas the chance of a
facial nerve deficit after vestibular schwannoma radiosurgery is
exceedingly low. Using a dosing regimen based on their vast experi-
ence with vestibular schwannoma radiosurgery (median tumor margin
dose, 13 Gy), 10 out of 11 tumors have remained stable or decreased in
size. Four patients had improved facial nerve function, and three
patients with Gardner-Robertson Class 1 hearing before radiosurgery
retained either Class 1 (n = 2 patients) or Class 2 (n = 1 patient) hear-
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ing at their last follow-up examination. Although these are clearly early
results and more follow-up reporting is needed, the decision to manage
patients with facial nerve schwannomas using radiosurgery as opposed




The authors report a small series of 11 patients with facial schwanno-mas who were treated using stereotactic radiosurgery. They have
shown that tumor control rates were high (91%) with no worsening in
preradiosurgery treatment function. Also interesting is that 4 of the 11
patients (36%) had improvement in their facial nerve function of one or
two levels on the House-Brackmann grading scheme. The pretreat-
ment hearing level was preserved in all patients who had functional
hearing before their radiosurgery; this finding is significant because
hearing loss is a risk associated with open surgery for these tumors.
Another finding, which is similar to observations of acoustic neuroma
patients, is that there can be a transient increase in tumor size during
the first 12 months as the tumor undergoes necrosis from treatment.
Although additional follow-up is needed for these patients, it appears
that radiosurgery is a viable treatment option for facial schwannomas,
as the procedure appears to convey a high rate of tumor control with
low risk to hearing and facial nerve function.
Steven D. Chang
Stanford, California
Litre et al. present detailed information on 11 presumed facial nerveschwannomas that were followed-up for at least 18 months after
radiosurgical treatment. No patients experienced worsening of facial
function and three patients’ symptoms improved. One patient experi-
enced enlargement of a cystic tumor; the remainder of the tumors were
controlled. This report reflects the largest series of facial nerve schwan-
nomas treated with radiosurgery and represents a significant contribu-
tion to the literature.
A cautionary note: not every enhancing lesion that tracks along the
facial nerve and causes facial paralysis is a facial schwannoma. Other
pathological entities, including hemangioma and simple inflammation
can have a very similar appearance on magnetic resonance images.
Radiosurgery may indeed become a preferred treatment for facial
schwannomas, given the morbidity of surgery, but longer follow-up
periods of larger numbers of patients are needed.
William A. Friedman
Gainesville, Florida
In this article, Litre et al. report on their experience with gamma knifesurgery for facial nerve schwannomas. As compared with their eighth
nerve counterparts, these tumors are relatively rare. In a busy center
such as Timone, these tumors comprise fewer than 1% of all cerebello-
pontine angle tumors that were treated.
It is not surprising that 10 out of 11 patients demonstrated no tumor
growth on their last follow-up neurological imaging. It has been shown
with vestibular and trigeminal nerve schwannomas that gamma knife
surgery affords a high rate of local tumor control. The significant find-
ing in this study is that no patients experienced new or worsening
facial palsy, and that three patients actually had improvements in pre-
operative facial weakness.
Our results at the University of Virginia for non-eighth nerve schwan-
nomas treated using the gamma knife have been similarly encouraging.
A dose of 11–15 Gy to the periphery typically effectuates local tumor
control and maintenance or improvement of neurological function. We
have found magnetization-prepared rapid-gradient echo and construc-
tive interference in steady-state magnetic resonance sequences very use-
ful for dose planning. In seventh or eighth nerve schwannomas, limit-
ing the cochlear and intracanalicular doses whenever possible may
prove efficacious in terms of auditory function preservation.
Such results certainly demand longer term follow-up. A larger patient
population would be preferable, but, given the relative rarity of these
tumors, single-institution experiences will be fairly limited. Clearly,
microsurgery should not be excluded; in the case where diagnosis is
uncertain or the tumor is large and exerting mass effect, extirpation
should be performed. However, the intermediate results from this facial
nerve schwannoma series suggest that gamma knife surgery may rep-
resent the treatment of choice for small to moderately sized tumors.
Jason P. Sheehan
Charlottesville, Virginia
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